Cardiovascular
How broadly does smoking raise heart and vessel disease risk?
Open access · cc by · source: Europe PMC
In a large Australian cohort, current smoking raised risk across nearly all CVD subtypes—especially peripheral arterial disease—and quitting lowered risk.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Conservative Burden of Proof methods still link SHS to multiple adult/child outcomes.
A Burden of Proof synthesis associated SHS with nine outcomes; conservative floors included ≥~8% higher IHD, ≥~5% stroke, and smaller but positive floors for type 2 diabetes and lung cancer (two-star ratings), with additional child respiratory and other endpoints.
Scope note — active smoking CVD subtype risks are larger/different exposure than SHS
Limits the claim's scope: a different population, assay, or outcome.
Active tobacco smoking maps onto many CVD subtypes, not only “heart disease” as one bucket.
Large cohort evidence linked tobacco smoking to risk across dozens of fatal and non-fatal cardiovascular disease subtypes.
Evidence for the claim as stated.
In older Indian adults, smokeless tobacco is common and clusters in rural, male, poorer, and informal work.
LASI wave 1 (n=65,561) found 38% ever tobacco use; 22.8% ever and 20.4% currently used smokeless tobacco. Among tobacco users, 51% used SLT, 40% smoked, and 9% used both. Use was higher in Scheduled Tribe groups and in agricultural/plant-machine work (~22%) than among professionals (~10%); 88.6% of ever-SLT users still used it.
Scope note — active smoked-tobacco CVD subtype risks are a different product and endpoint than SLT occupational prevalence
Limits the claim's scope: a different population, assay, or outcome.
India’s tobacco epidemic rose then fell for men while women declined, with huge state gaps and smokeless still common.
NFHS rounds showed age-standardized male tobacco use rising 32% from 1998–99 to 2005–06 (27.90% to 36.81%) then falling 26% by 2015–16 (to 27.31%); women’s use declined throughout. By 2015–16 male smoking was 12.20% and smokeless 15.12%, with male smoking from 5.71% (Maharashtra) to 37.70% (Mizoram).
Scope note — Western smoked-tobacco CVD subtype risks ≠ Indian national prevalence trends
Limits the claim's scope: a different population, assay, or outcome.
Maternal cigarette dose and preterm birth odds vs Conservative SHS relative-risk floors across outcomes vs Active smoking across CVD subtypes
Evidence for the claim as stated.
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
Evidence for the claim as stated.
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
Evidence for the claim as stated.
A larger weight-adjusted waist index associates with higher stroke odds in US survey data.
In US NHANES adults (2011–2020), higher weight-adjusted waist index was associated with higher odds of self-reported stroke after multivariable adjustment (about 25% higher odds per 1-unit WWI; highest vs lowest quartile OR about 1.62).
Scope note — different design — prospective risks, not cross-sectional NHANES odds
Limits the claim's scope: a different population, assay, or outcome.
A more inflammatory diet score associates with higher stroke odds in related survey data.
In a related NHANES analysis, higher dietary inflammatory index quartiles were associated with higher stroke odds (highest vs lowest quartile OR about 1.87), with a nonlinear pattern and a LASSO-based nomogram AUC near 80%.
Scope note — different design — prospective cohort, not NHANES cross-section
Limits the claim's scope: a different population, assay, or outcome.
These markers flag observational risk — they are not proven treatment targets.
In the prospective 45 and Up Study, current smoking was associated with elevated risks across many CVD subtypes including stroke, with especially large relative risks for peripheral arterial disease; former smokers showed intermediate risks, consistent with risk reduction after quitting.
Evidence for the claim as stated.
NHANES stroke associations are cross-sectional and self-reported; 45 and Up smoking estimates are prospective event risks. A stronger causal reading is more defensible for the smoking cohort design than for the NHANES odds ratios—without requiring the NHANES associations to be “wrong.”
Evidence for the claim as stated.
Tobacco smoking associates with many cardiovascular disease subtypes.
Large-scale tobacco analyses link smoking to broad cardiovascular subtype risk—downstream disease burden beyond mood symptoms.
Evidence for the claim as stated.
Association ORs for depression, cessation trial/intervention results, and CV disease risk from tobacco should not be treated as one causal chain without designs that can test directionality.
Evidence for the claim as stated.
The 45 and Up Study accumulated 1.35 million person-years and 27,511 major CVD events. Current smoking raised risks across IHD/AMI, stroke and heart failure, and especially PAD (RR about 5); former smokers sat in between. Subtype risks are not identical, and residual confounding is still possible despite adjustment.
Evidence for the claim as stated.
Follow-up of thousands of event-free adults is a different design from a 74-person telemedicine case series, even if both get filed as cohorts. The HLI, diet-depression, smoking-CVD and Rotterdam papers estimate rates or attributable fractions over years. The WeChat paper describes outcomes after care already delivered, with no control group, so it cannot show that monitoring caused recovery.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Maternal cigarette dose and preterm birth odds vs Conservative SHS relative-risk floors across outcomes vs Active smoking across CVD subtypes
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
NHANES stroke associations are cross-sectional and self-reported; 45 and Up smoking estimates are prospective event risks. A stronger causal reading is more defensible for the smoking cohort design than for the NHANES odds ratios—without requiring the NHANES associations to be “wrong.”
Association ORs for depression, cessation trial/intervention results, and CV disease risk from tobacco should not be treated as one causal chain without designs that can test directionality.
- Supports · Does smoking track with depression in US adults?
- Supports · Smart-T smoking EMI app
Follow-up of thousands of event-free adults is a different design from a 74-person telemedicine case series, even if both get filed as cohorts. The HLI, diet-depression, smoking-CVD and Rotterdam papers estimate rates or attributable fractions over years. The WeChat paper describes outcomes after care already delivered, with no control group, so it cannot show that monitoring caused recovery.
- Supports · Healthy lifestyle and multimorbidity risk
- Supports · Diet quality and depression risk
- Supports · WeChat monitoring of home COVID patients
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on Tobacco smoke exposure
LASI wave 1 (n=65,561) found 38% ever tobacco use; 22.8% ever and 20.4% currently used smokeless tobacco. Among tobacco users, 51% used SLT, 40% smoked, and 9% used both. Use was higher in Scheduled Tribe groups and in agricultural/plant-machine work (~22%) than among professionals (~10%); 88.6% of ever-SLT users still used it.
Placed as supporting evidence on Tobacco smoke exposure
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
Placed as a scope qualifier on Tobacco smoke exposure
NFHS rounds showed age-standardized male tobacco use rising 32% from 1998–99 to 2005–06 (27.90% to 36.81%) then falling 26% by 2015–16 (to 27.31%); women’s use declined throughout. By 2015–16 male smoking was 12.20% and smokeless 15.12%, with male smoking from 5.71% (Maharashtra) to 37.70% (Mizoram).
Placed as supporting evidence on Tobacco smoke exposure
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
Study at a glance
- Design
- Cohort — 45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes
- N
- N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years
- Population
- Australian adults in the 45 and Up Study
- Outcome
- Hospitalisation or death from major CVD subtypes by smoking status
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
How broadly does smoking raise heart and vessel disease risk?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
What happens with quitting according to authors?
Quitting reduces the risk.
Which cohort supplied participants?
The Sax Institute’s 45 and Up Study is a cohort study of 267,153 men and women aged 45 and over at baseline, randomly sampled from the general population of New South Wales (NSW), Australia, using the Department of Human Services enrolment database.
Key findings
Among 27,511 major CVD events, current smoking elevated risks for IHD/AMI, stroke, heart failure, and especially PAD (RR ~5). Risks were intermediate in former smokers; quitting reduces risk. Even paroxysmal tachycardia risk was implicated.
Methodology
Using the 45 and Up Study with 1.35 million person-years of follow-up, investigators compared current and past smokers with never smokers for dozens of fatal/non-fatal CVD subtypes.
Limitations
Observational residual confounding is possible despite adjustment; subtype risks vary and are not identical.
Related papers in this topic
Same topic cluster — not a recommendation engine.